Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

The Lancet - Tập 393 Số 10183 - Trang 1819-1830 - 2019
Tony Mok1, Yi‐Long Wu2, Iveta Kudaba3, Dariusz Kowalski4, Byoung Chul Cho5, H.Z. Turna6, Gilberto de Castro7, Vichien Srimuninnimit8, К. К. Лактионов9, Igor Bondarenko10, Kaoru Kubota11, Gregory M. Lubiniecki12, Jin Zhang13, Debra Kush12, Gilberto Lopes14, Grigory Adamchuk, Myung‐Ju Ahn, Aurelia Alexandru, Özden Altundağ, Anna Alyasova, Orest Andrusenko, Keisuke Aoe, António Araújo, Osvaldo Rudy Aren, Óscar Arrieta, Touch Ativitavas, Oscar Avendaño, Fernando Barata, Carlos H. Barrios, C. Beato, Per Bergström, Daniel Betticher, Л. В. Болотина, Michiel Botha, Sayeuri Buddu, Christian Caglevic, Rafael Rosell, Hugo R. Castro, Filiz Çay Şenler, Carlos Alexandre Sydow Cerny, Alvydas Česas, George Chan, Jianhua Chang, Gongyan Chen, Xi Chen, Susanna Cheng, Ying Cheng, Nelly Cherciu, Chao‐Hua Chiu, Saulius Cicėnas, Daniel Ciurescu, Graham Cohen, Marcos André Costa, Pongwut Danchaivijitr, Flávia De Angelis, Sérgio Jobim Azevedo, Mircea Dediu, Tsvetan Deliverski, Pedro Rafael Martins De Marchi, F Vallés, Zhenyu Ding, Boyan Doganov, Lydia Dreosti, Ricardo Duarte, Regina Edusma-Dy, S. A. Emelyanov, Mustafa Erman, Yun Fan, Luis Fein, Jifeng Feng, David Fenton, Gustavo dos Santos Fernandes, Carlos Gil Ferreira, Fábio Franke, H. Freitas, Yasuhito Fujisaka, Héctor Galindo, Christina Galvez, Doina Ganea, Nuno Gil, Gustavo Girotto, Erdem Göker, Tuncay Göksel, Guillaume Ghislain Aubin, Luis Gomez Wolff, Håkan Griph, Mahmut Gümüş, Jacqueline A. Hall, Gregory Hart, Libor Havel, Jianxing He, Yong He, Carlos Hernández Hernández, Venceslau Hespanhol, Tomonori Hirashima, Chung Man James Ho, Atsushi Horiike, Yukio Hosomi, Katsuyuki Hotta, Mei Hou, Soon Hin How, Te‐Chun Hsia, Yi Hu, Masao Ichiki, Fumio Imamura, О. І. Іващук, Yasuo Iwamoto, Jana Jaal, Jacek Jassem, Christa Jordaan, Rosalyn A. Juergens, Diego Kaen, Ewa Kalinka‐Warzocha, Nina Karaseva, Bogusława Karaszewska, Andrzej Rynkiewicz, Kazuo Kasahara, Nobuyuki Katakami, Terufumi Kato, Tomoya Kawaguchi, Joo Hang Kim, Kazuma Kishi, Vı́tězslav Kolek, Marchela Koleva, Petr Kolman, Leona Koubková, Rubén Dario Kowalyszyn, Krassimir Koynov, Doran Ksienski, Takayasu Kurata, Gerli Kuusk, Lyudmila Kuzina, Ibolya Laczó, Guia Ladrera, Gregory Landers, Sergey Lazarev, Guillermo Lerzo, Krzysztof Lesniewski- Kmak, Wei Li, Chong Kin Liam, Igor Lifirenko, Oleg Lipatov, Xiaoqing Liu, Zhe Liu, Sing Hung Lo, Valeria Lopes, K. Lopez, Shun Lü, Gastón L. Martinengo, Luís Más, Marina Matrosova, Rumyana Micheva, Zhasmina Mihaylova Milanova, Lucian Miron, Matias Molina, Shuji Murakami, Yasuharu Nakahara, Tien Quang Nguyen, Takashi Nishimura, Adrian F. Ochsenbein, Tatsuo Ohira, Ronny Öhman, Choo Khoon Ong, Gyula Ostoros, Xuenong Ouyang, Е. Г. Овчинникова, Özgür Özyılkan, Luboš Petruželka, Xuan Dung Pham, Pedro Dornelles Picon, Béla Pikó, Artem Poltoratsky, Olga Ponomarova, Patrice Popelková, Gunta Purkalne, Shukui Qin, Rodryg Ramlau, Bernardo Rappaport, Felipe Rey, Eduardo Richardet, Jaromı́r Roubec, Paul Ruff, Andrii Rusyn, Hideo Saka, Jorge Salas, Mario Sandoval, Lucas Vieira dos Santos, Toshiyuki Sawa, Kasan Seetalarom, Mesut Şeker, Nobuhiko Seki, Freddy Seolwane, Lucinda Shepherd, Sergii Shevnya, Andrea Shimada, Yaroslav Shparyk, Ivan Sinielnikov, Daniela Sîrbu, Òren Smaletz, João Paulo Holanda Soares, Aumkhae Sookprasert, Giovanna Speranza, Virote Sriuranpong, Zinaida Stara, Wu‐Chou Su, Shunichi Sugawara, Waldemar Szpak, Kazuhisa Takahashi, Nagio Takigawa, Hiroshi Tanaka, Jerry Tan Chun Bing, Qiyou Tang, Pavel Taranov, Hermes Tejada, Lye Mun Tho, Yoshitaro Torii, Dmytro Trukhyn, Maria Turdean, Hande Turna, G. Ursol, J Vaňásek, Mirta Varela, Marcela Vallejo, L. Vera, Ana-Paula Victorino, Tomáš Vlásek, Ihor Vynnychenko, Buhai Wang, Jie Wang, Kai Wang, Kazuhiko Yamada, James Chih‐Hsin Yang, Takuma Yokoyama, Toshihide Yokoyama, Hiroshige Yoshioka, Perran Fulden Yumuk, Ángela R. Zambrano, Juan José Zarbá, Oleg Zarubenkov, Marius Žemaitis, Li Zhang, Xin Zhang, Jun Zhao, Caicun Zhou, Jianying Zhou, Qing Zhou, Alfred Zippelius
1Department of Clinical Oncology, State Key Laboratory of South China, Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China
2Department of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guandong, China
3Department of Internal Diseases, Riga East Clinical University–Latvian Oncology Center, Riga, Latvia
4Department of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
5Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea
6Department of Internal Medicine, Division of Medical Oncology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
7Department of Medical Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil
8Division of Medical Oncology, Department of Medicine, Siriraj Hospital, Bangkok, Thailand
9Department of Thoracic and Abdominal Oncology, N N Blokhin Russian Cancer Research Center, Moscow, Russia
10Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, Dnipro, Ukraine
11Department of Pulmonary Medicine and Oncology, Nippon Medical School Hospital, Tokyo, Japan
12Global Clinical Development, Merck & Co, Kenilworth, NJ, USA
13Biostatistics and Research Design Statistics, Merck & Co, Kenilworth, NJ, USA
14Department of Medical Oncology, Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530

Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X

Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440

Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N Engl J Med, 377, 829, 10.1056/NEJMoa1704795

Soria, 2017, First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, 389, 917, 10.1016/S0140-6736(17)30123-X

Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824

Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7

Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774

Reck, 2019, Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater, J Clin Oncol, 37, 537, 10.1200/JCO.18.00149

Roach, 2016, Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer, Appl Immunohistochem Mol Morphol, 24, 392, 10.1097/PAI.0000000000000408

Carbone, 2017, First-line nivolumab in stage IV or recurrent non-small-cell lung cancer, N Engl J Med, 376, 2415, 10.1056/NEJMoa1613493

Efron, 1977, The efficiency of Cox's likelihood function for censored data, J Am Stat Assoc, 72, 557, 10.1080/01621459.1977.10480613

Miettinen, 1985, Comparative analysis of two rates, Stat Med, 4, 213, 10.1002/sim.4780040211

Hwang, 1990, Group sequential designs using a family of type I error probability spending functions, Stat Med, 9, 1439, 10.1002/sim.4780091207

Goffin, 2010, First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review, J Thorac Oncol, 5, 260, 10.1097/JTO.0b013e3181c6f035

Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer, N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005

Davies, 2017, Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently published studies, PLoS One, 12, e0175679, 10.1371/journal.pone.0175679

Lazzari, 2017, Historical evolution of second-line therapy in non-small cell lung cancer, Front Med (Lausanne), 4, 4

Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643

Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665

Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 375, 1856, 10.1056/NEJMoa1602252

Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683

Paz-Ares, 2018, Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer, N Engl J Med, 379, 2040, 10.1056/NEJMoa1810865

Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884

Zinner, 2015, J Thorac Oncol, 10, 134, 10.1097/JTO.0000000000000366

Thông tin
Thông tin xuất bản

The Lancet

Tập 393 Số 10183

1819-1830

Thông tin tác giả